|
In very rare cases, mycoplasmas resistant to Plasmocin™ have been reported. To eradicate these mycoplasmas, InvivoGen has developed a new antimycoplasma agent called Plasmocure™.
Plasmocure™ combines two antibiotics that act through different mechanisms of action than those in Plasmocin™. A two week treatment with Plasmocure™ was found sufficient to completely eliminate the mycoplasmas. A moderate toxicity can be observed during the course of the treatment but full recovery of the cell line is expected once mycoplasmas are eliminated |